Indivior/$INDV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Indivior
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
- Ticker
- $INDV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 833
- Headquarters
- North Chesterfield, United States
- Website
- www.indivior.com
Indivior Metrics
BasicAdvanced
$4.2B
9.95
$3.55
1.18
-
Price and volume
Market cap
$4.2B
Beta
1.18
52-week high
$42.81
52-week low
$27.68
Average daily volume
2.4M
Financial strength
Current ratio
0.615
Quick ratio
0.454
Long term debt to equity
-0.1
Total debt to equity
-8.35
Interest coverage (TTM)
44.94%
Profitability
EBITDA (TTM)
652
Gross margin (TTM)
88.14%
Net profit margin (TTM)
32.75%
Operating margin (TTM)
52.33%
Effective tax rate (TTM)
16.36%
Revenue per employee (TTM)
$1,650,000
Management effectiveness
Return on assets (TTM)
32.71%
Return on equity (TTM)
-337.08%
Valuation
Price to earnings (TTM)
9.952
Price to revenue (TTM)
3.157
Price to book
-69.56
Price to tangible book (TTM)
-67.32
Price to free cash flow (TTM)
139.198
Free cash flow yield (TTM)
0.72%
Free cash flow per share (TTM)
0.254
Growth
Revenue change (TTM)
16.44%
Earnings per share change (TTM)
250.94%
3-year revenue growth (CAGR)
9.66%
10-year revenue growth (CAGR)
2.76%
3-year earnings per share growth (CAGR)
27.37%
10-year earnings per share growth (CAGR)
51.70%
What the Analysts think about Indivior
Analyst ratings (Buy, Hold, Sell) for Indivior stock.
Analyst projections of the future price of Indivior stock.
Bulls say / Bears say
SUBLOCADE revenue rose 21% year on year to a record $253 million in Q2, and Indivior raised its 2026 revenue and earnings guidance. The higher forecast reflects continued demand and gives the growth case fresh support. (Indivior)
The proposed Supernus merger could diversify Indivior beyond addiction treatments and deliver about $125 million in annual cost savings. Indivior shareholders are also due a $1 billion special cash dividend if the deal closes. (Reuters)
Real-world research involving more than 45,000 people with opioid use disorder found buprenorphine-based treatment associated with lower overdose risk; the monthly injection had among the lowest odds of fatal and non-fatal overdose versus no treatment. This evidence could strengthen the case for Sublocade’s use, though the study has limitations. (Indivior)
Indivior faces thousands of Suboxone dental-injury claims: by July, about 1,967 cases involving 26,307 plaintiffs were consolidated in US litigation. The company says it cannot yet estimate potential losses, leaving a material financial risk unresolved. (SEC)
Indivior stopped internal development of two pipeline candidates: INDV-2000 failed its Phase 2 primary endpoint, and the company will not take INDV-6001 into Phase 3. These setbacks leave less internally developed potential to broaden growth beyond its existing products. (Indivior)
Suboxone Film continues to lose share to generic competition, while management expected gross-to-net adjustments to weigh on both Suboxone and Sublocade in 2026. Those pressures could erode revenue and offset some product growth. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Indivior Financial Performance
Revenues and expenses
Indivior Earnings Performance
Company profitability
Upcoming events
Indivior News
AllArticlesVideos
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Business Wire1 month ago
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire2 months ago
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Business Wire3 months ago
Funds containing Indivior
AllUSDEURGBP
Fund name | Fund size | $INDV weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.26% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.26% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.23% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.23% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.